Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States, Canada and Japan. This agreement includes rights
The results from this study confirmed CTP-656’s superior pharmacokinetic profile to Kalydeco as was previously reported from Concert’s single ascending dose trial, which demonstrated favorable pharmacokinetic properties with
The LAVOLTA I-II studies were identical, double-blind, randomised, multicentre, placebo-controlled studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma. LAVOLTA I met its
Lice are a nuisance and causes embarrassment for many, however carry no serious harm. While lice have built a resistance for over-the-counter products there are several prescription products
TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir
"This positive CHMP opinion brings us one step closer to delivering a ribavirin-free treatment option for GT1b patients with compensated cirrhosis that has demonstrated high cure rates with
Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam. Menarini
A ground-breaking project announced by the British Prime Minister David Cameron in 2012, the 100,000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS)
Published in the February 2016 edition of Clinical Trials: Journal of the Society for Clinical Trials, the analysis identifies different factors, such as therapeutic area, patient recruitment, administrative
About 85 percent of NHL is of B-cell lineage, and CD19 is broadly expressed across all subtypes of B-cell malignancies. SGN-CD19B is a novel antibody-drug conjugate (ADC) targeted
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.